MIT researchers report a nanoparticle-based approach that reprograms natural killer (NK) immune cells in the body to attack specific T cells involved in disease. The method is designed to redirect NK activity toward cancer-related T cells and toward T cells that have become autoreactive, which can contribute to conditions such as lymphoma and autoimmune hepatitis.
According to MIT News and Phys.org, the work focuses on controlling NK immune cells that otherwise target more broadly, aiming instead for a more tailored response. The outlets describe the same underlying concept: engineering or delivering reprogramming signals through nanoparticles so NK cells can recognize and respond to problematic T-cell populations. Both sources present the approach as promising, while indicating it is at the research stage.
While neither outlet provides detailed trial results in the provided summaries, both emphasize the potential to treat diseases linked to dysfunctional or harmful T-cell behavior by using NK cells as the effectors.
